Michael M. Frank

Q: What Schools Are Affiliated With Michael M. Frank

Michael M. Frank is affiliated with the following schools: Duke University, University of Rochester, University of Pennsylvania, University of Maryland, College Park, Tufts University, Georgetown University, Johns Hopkins University

Michael M. Frank's AcademicInfluence.com Rankings

Michael M. Frank

Biology

#4381

World Rank

#6537

Historical Rank

Immunology

#183

World Rank

#191

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Michael M. Frank Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael M. Frank's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Practice parameter for the diagnosis and management of primary immunodeficiency. (2015) (638)
Hereditary angioedema: the clinical syndrome and its management. (1976) (576)
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. (1977) (530)
The role of complement in inflammation and phagocytosis. (1991) (507)
Sjögren's syndrome (Sicca syndrome): current issues. (1980) (499)
Treatment of Hereditary Angioedema with Danazol (1976) (495)
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. (1979) (485)
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. (1984) (376)
Nodular lymphoma--evidence for origin from follicular B lymphocytes. (1974) (358)
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. (1990) (319)
8. Hereditary angioedema. (2008) (317)
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. (1996) (302)
Aerosol α1 -antitrypsin treatment for cystic fibrosis (1991) (291)
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. (1985) (276)
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes (1983) (275)
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. (1981) (262)
Practice parameter for the diagnosis and management of primary immunodeficiency. (2005) (259)
Non-endemic Burkitts's lymphoma. A B-cell tumor related to germinal centers. (1976) (246)
Therapeutic potential of complement modulation (2010) (224)
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. (1976) (220)
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha (1988) (219)
Complement and bacteria: chemistry and biology in host defense. (1984) (216)
Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. (1980) (215)
International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. (2012) (206)
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. (1972) (206)
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. (1972) (205)
C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. (1987) (200)
Pathophysiology of Immune Hemolytic Anemia (1977) (195)
Receptors for immunoglobulin and complement on human alveolar macrophages. (1975) (194)
Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. (1995) (193)
A prospective clinical and immunologic analysis of patients with serum sickness. (1984) (178)
Opsonic requirements for intravascular clearance after splenectomy. (1981) (178)
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. (1986) (177)
Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. (1986) (172)
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. (1989) (172)
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. (1974) (171)
Acquired C1 Esterase Inhibitor Deficiency and Angioedema: A Review (1979) (171)
Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. (1987) (169)
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. (1974) (161)
Regulation of complement activity by vaccinia virus complement-control protein. (1992) (160)
IMPAIRED IMMUNE RESPONSE OF SPLENECTOMISED PATIENTS TO POLYVALENT PNEUMOCOCCAL VACCINE (1981) (159)
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. (2010) (159)
SYSTEMIC CAPILLARY LEAK SYNDROME AND MONOCLONAL IgG GAMMOPATHY: Studies in a Sixth Patient and a Review of the Literature (1977) (149)
Complement 1 Inhibitor Is a Regulator of the Alternative Complement Pathway (2001) (149)
Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria (1987) (146)
Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. (1974) (145)
Leukemic reticuloendotheliosis: presence of a receptor for cytophilic antibody. (1974) (144)
Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. (1987) (143)
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. (1986) (140)
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. (1982) (140)
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. (1987) (140)
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. (1983) (133)
Functional markers: a new perspective on malignant lymphomas. (1977) (132)
Long-term therapy of hereditary angioedema with danazol. (1980) (131)
Capsule Production and Growth Phase Influence Binding of Complement to Staphylococcus aureus (2001) (131)
US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. (2013) (126)
Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. (1975) (125)
Complement activation. (1981) (124)
Samter's Immunologic Diseases (2001) (124)
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I (1984) (121)
Heterogeneity of immunologic markers and surface morphology in childhood lymphoblastic lymphoma. (1976) (119)
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. (1972) (117)
The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. (1992) (115)
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. (1991) (115)
Studies on the mechanism of bacterial resistance to complement-mediated killing. IV. C5b-9 forms high molecular weight complexes with bacterial outer membrane constituents on serum-resistant but not on serum-sensitive Neisseria gonorrhoeae. (1983) (115)
IN VITRO STUDIES OF COMPLEMENT FUNCTION IN SERA OF C4-DEFICIENT GUINEA PIGS (1971) (115)
The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. (1976) (115)
The role of complement in the induction of antibody responses. (1983) (107)
Complement depletion in cryptococcal sepsis. (1978) (107)
Structural and functional properties of the „hairy”︁ cells of leukemic reticuloendotheliosis (1978) (106)
Identification of subpopulations of mononuclear cells in cutaneous infiltrates. I. Differentiation between B cells, T cells, and histiocytes. (1973) (106)
The role of the spleen in experimental pneumococcal bacteremia. (1981) (106)
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. (1983) (104)
ONTOGENY OF B LYMPHOCYTES (1974) (104)
Studies on the fibronectin receptors of human peripheral blood leukocytes. Morphologic and functional characterization (1984) (103)
Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. (1986) (103)
Demonstration of circulating immune complexes in Sjögren's syndrome. (1979) (103)
Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies. (1974) (102)
Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. (1985) (101)
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. (1978) (101)
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. (1967) (99)
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. (2006) (98)
Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. (1973) (98)
Mechanisms involved in elimination of organisms from experimental cutaneous Candida albicans infections in guinea pigs. (1976) (96)
Hereditary complement (C2) deficiency with dermatomyositis. (1975) (94)
Human Serum Sickness: A Prospective Analysis of 35 Patients Treated with Equine Anti‐Thymocyte Globulin for Bone Marrow Failure (1988) (93)
The critical role of complement in experimental pneumococcal sepsis. (1980) (92)
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. (2020) (89)
Complement receptors. (1981) (89)
The function of antibody and complement in the lysis of bacteria. (1987) (86)
A simple method for the determination of complement receptor-bearing mononuclear cells. (1976) (86)
Hereditary angioedema: the clinical syndrome and its management in the United States. (2006) (85)
Complement in the pathophysiology of human disease. (1987) (85)
High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance (1989) (85)
Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. (2004) (85)
Complement levels and activity in the normal and LPS-injured lung. (2007) (84)
Studies of human C5a as a mediator of inflammation in normal human skin. (1985) (84)
Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease. (1980) (81)
Role of complement in host defense against experimental disseminated candidiasis. (1978) (80)
Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. (1983) (79)
Similarities of surface characteristics of neoplastic well-differentiated lymphocytes from solid tissues and from peripheral blood. (1976) (79)
Bactericidal and opsonic properties of C4-deficient guinea pig serum. (1972) (79)
Antibody-Dependent Lymphoid Cell-Mediated Cytotoxicity: Role of Lymphocytes Bearing a Receptor for Complement (1973) (78)
Current state of hereditary angioedema management: a patient survey. (2015) (76)
Complement-immunoglobulin interactions. (1995) (76)
The complement system in host defense and inflammation. (1979) (75)
The long-term safety of danazol in women with hereditary angioedema. (1990) (73)
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. (1975) (73)
Total respiratory support from swine lungs in primate recipients. (1998) (73)
The fourth component of complement in the cerebrospinal fluid in systemic Lupus erythematosus. (1973) (72)
A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus. (1982) (71)
The glomerular complement receptor in immunologically mediated renal glomerular injury. (1976) (71)
IN VIVO STUDIES IN C4-DEFICIENT GUINEA PIGS (1971) (70)
Endotoxemia associated with the Jarisch-Herxheimer reaction. (1976) (69)
Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes. (1996) (69)
Availability of Complement Bound to Staphylococcus aureus To Interact with Membrane Complement Receptors Influences Efficiency of Phagocytosis (2003) (68)
Sjögren's syndrome: a defect in reticuloendothelial system Fc-receptor-specific clearance. (1979) (68)
Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. (1979) (66)
Generation of isogenic K54 capsule‐deficient Escherichia coli strains through TnphoA‐mediated gene disruption (1993) (66)
Identification of cells infiltrating the minor salivary glands in patients with Sjögren's syndrome. (1974) (66)
The relationship between antibody affinity and the efficiency of complement fixation. (1970) (63)
The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. (1983) (63)
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). (1979) (63)
Effect of cortisone therapy on serum complement components. (1973) (62)
High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes (1991) (61)
Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. (1986) (60)
The Role of Late Complement Components and the Alternate Complement Pathway in Experimental Cryptococcosis (1973) (60)
Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation. (1973) (59)
High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. (1991) (59)
Defective reticuloendothelial system Fc-receptor function in patients with acquired immunodeficiency syndrome. (1985) (58)
Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. (1985) (57)
Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. (1985) (56)
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. (1986) (56)
A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose. (1989) (56)
Human C5a modulates monocyte Fc and C3 receptor expression. (1985) (56)
Localization of receptors for activated complement on visceral epithelial cells of the human renal glomerulus. (1977) (55)
Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. (1988) (55)
Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. (1974) (55)
New therapies for hereditary angioedema: disease outlook changes dramatically. (2008) (55)
Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. (1983) (55)
Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. (1985) (54)
C3d receptors are expressed on human monocytes after in vitro cultivation. (1983) (54)
Clq acts synergistically with phorbol dibutyrate to activate CR1‐mediated phagocytosis by human mononuclear phagocytes (1988) (54)
Wild-type adenoviruses from groups A–F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent (2008) (54)
Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro (1985) (53)
C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2 (1988) (53)
A quantitative fluorescent method for measurement of bacterial adherence and phagocytosis. (1986) (53)
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. (1973) (52)
Immunoglobulin and complement receptors on human eosinophils and their role in cellular adherence to schistosomules. (1977) (51)
The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. (1981) (51)
Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC (2010) (51)
The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. (1982) (50)
Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions. (1976) (49)
Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. (2016) (49)
Relationship of serum complement levels to events of the malarial paroxysm. (1974) (48)
Studies on phagocytosis in patients with acute bacterial infections. (1989) (48)
A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. (1984) (48)
Oral manifestations and dental management of patients with hereditary angioedema. (1991) (47)
Immunoglobulin in the control of complement action (2000) (47)
Heparan Sulfate, Including That in Bruch’s Membrane, Inhibits the Complement Alternative Pathway: Implications for Age-Related Macular Degeneration (2010) (47)
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules (1983) (47)
Bypassing complement: evolutionary lessons and future implications. (2006) (47)
The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. (1974) (47)
Expression of human complement factor H prevents age-related macular degeneration-like retina damage and kidney abnormalities in aged Cfh knockout mice. (2015) (46)
STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. I. INHIBITION BY TRISODIUM ETHYLENEDIAMINETETRAACETATE (EDTA). (1964) (45)
Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus. (1987) (45)
Monocyte receptors for the Fc portion of IgG studies with monomeric human IgG1: normal in vitro expression of Fc gamma receptors in HLA-B8/Drw3 subjects with defective Fc gamma-mediated in vivo clearance. (1982) (45)
Lack of binding of human C3, in its native state, to C3b receptors. (1981) (45)
Immunologic reactivity in the hypereosinophilic syndrome. (1979) (45)
Evaluation of the adverse effects of long-term hyposensitization. (1978) (43)
THE SUBUNITS IN RABBIT ANTI-FORSSMAN IGM ANTIBODY (1968) (43)
Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. (1987) (43)
Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. (1983) (43)
Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae. (1985) (42)
The reticuloendothelial system and bloodstream clearance. (1993) (42)
TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity (1993) (41)
Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria. (1986) (41)
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. (1970) (41)
Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus. (1984) (41)
The mechanism by which microorganisms avoid complement attack (1992) (40)
C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae. (1987) (40)
Before and after, the impact of available on-demand treatment for HAE. (2015) (40)
Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. II. Evidence for involvement of C1 and components of the alternate complement pathway. (1973) (40)
Tumor-promoting phorbol esters induce rapid internalization of the C3b receptor via a cytoskeleton-dependent mechanism. (1985) (40)
Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. (1991) (39)
Primary Biliary Cirrhosis and the Complement System (1979) (39)
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency (2016) (39)
Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. (2010) (39)
Serum complement activation in central nervous system disease in Sjögren's syndrome. (1988) (38)
The effects of IL-1, IL-2, and tumor necrosis factor on polymorphonuclear leukocyte Fc gamma receptor-mediated phagocytosis. IL-2 down-regulates the effect of tumor necrosis factor. (1991) (38)
Complement resistance in microbes (2005) (38)
The complement fragment C3d facilitates phagocytosis by monocytes. (1987) (37)
Hereditary angioneurotic edema of the gastrointestinal tract. (1972) (37)
C1q enhances the phagocytosis of Cryptococcus neoformans blastospores by human monocytes. (1988) (37)
Complement disorders and hereditary angioedema. (2010) (37)
Receptors for immunoglobulin and complement on mouse leukemias and lymphomas. (1972) (36)
Paroxysmal nocturnal hemoglobinuria. Alternate-complement-pathway-mediated lysis induced by magnesium. (1973) (36)
Demonstration of defective C3-receptor-mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome. (1987) (35)
STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. II. RESOLUTION OF THE E TRANSFORMATION REACTION INTO MULTIPLE STEPS. (1964) (34)
Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide (1984) (33)
Contributions of the classical and alternate complement pathways to the biological effects of endotoxin. (1973) (33)
Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. I. Antibody and serum requirements. (1973) (33)
Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing. (1987) (33)
Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. (1979) (31)
Serum complement and immunity in experimental simian malaria. II. Preferential activation of early components and failure of depletion of late components to inhibit protective immunity. (1975) (31)
IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111 (1985) (31)
Hereditary angioedema from the patient's perspective: A follow-up patient survey. (2018) (31)
Host defense against bacterial endotoxemia-contribution of the early and late components of complement to detoxification. (1972) (31)
Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. (2004) (31)
Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide. (1982) (31)
Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. (1985) (30)
Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. (1986) (30)
C3b binding, but not its breakdown, is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from Salmonellae. (1986) (30)
Serum complement and immunity in experimental simian malaria. I. Cyclical alterations in C4 related to schizont rupture. (1975) (30)
Circulating immune complexes and glomerulonephritis in a patient with congenital absence of the third component of complement. (1983) (30)
Deposition of complement components in the cutaneous lesions of chronic mucocutaneous candidiasis. (1976) (30)
Humoral immunostimulation. IV. Role of complement (1975) (29)
Analysis of complement-dependent antibody-mediated lysis of target cells acutely infected with measles. (1976) (29)
Binding sites for immune complexes containing IgG in the renal interstitium. (1979) (28)
Mixed cryoglobulinemia: association of glomerulonephritis with defective reticuloendothelial system Fc receptor function. (1979) (28)
Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. (1986) (27)
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. (1988) (26)
Complement-mediated tissue damage: contribution of the classical and alternate complement pathways in the Forssman reaction. (1972) (25)
Serum sickness and haematopoietic recovery with antithymocyte globulin in bone marrow failure patients (1986) (25)
Multiple types of immune complexes in patients with mixed cryoglobulinemia. (1980) (25)
Production of congenital malformations using tissueantisera. 8. Effectiveness of reduced, alkylated and digested anti-kidney antibodies. (1970) (25)
Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. (1983) (24)
Human eosinophil adherence to serum-treated sepharose: granule-associated enzyme release and requirement for activation of the alternative complement pathway. (1977) (24)
Biotinylation of human C3. (1982) (24)
Biosynthesis of the second (C2) and fourth (C4) components of complement in vitro by tissues isolated from guinea-pigs with genetically determined C4 deficiency. (1972) (24)
Di George syndrome associated with glioma and two kinds of viral infection. (1977) (24)
Update on preventive therapy (prophylaxis) of hereditary angioedema. (2011) (23)
IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. (1999) (23)
Surfactant protein A enhances the phagocytosis of C1q-coated particles by alveolar macrophages. (2002) (23)
Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. (1986) (23)
Antibody-dependent lymphoid cell-mediated cytotoxicity: role of complement. (1974) (23)
High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. (1989) (23)
The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors. (1975) (23)
Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. (2008) (22)
C1‐esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle (2003) (22)
Production of chemotactic activity by guinea pig immunoglobulins following activation of the C3 complement shunt pathway. (1972) (21)
Terminal Complement Complexes (SC5b‐9) in Cerebrospinal Fluid in Autoimmune Nervous System Diseases (1988) (21)
Reviews of Infectious Diseases (2016) (21)
Surface receptors of human neoplastic lymphoreticular cells. (1977) (21)
A study of human serum sickness. (1985) (21)
The alternate complement pathway in cell damage: antibody-mediated cytolysis of erythrocytes and nucleated cells. (1972) (20)
Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. (2017) (20)
Complement in clinical medicine. (1975) (20)
Annihilating host defense (2001) (20)
Generation of chemotactic factors in guinea pig serum via activation of the classical and alternate complement pathways. (1973) (19)
Prevention of hyperacute xenograft rejection by intravenous immunoglobulin. (1995) (19)
Reticuloendothelial system fc receptor function in rheumatoid arthritis. (1983) (18)
Novel Adenovirus Vectors ‘Capsid-Displaying’ a Human Complement Inhibitor (2010) (17)
High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway (1991) (17)
Quantitation of activation of the human terminal complement pathway by ELISA. (1985) (17)
Activation of the Alternate Complement Pathway by Human Immunoglobulins (1976) (16)
The role of complement in host resistance to bacteria (2005) (16)
Hereditary angioedema: a half century of progress. (2004) (16)
Reduced concentrations of the first component of complement in hypogammaglobulinemia: Correction by infusion of γ-globulin (1978) (16)
Cleavage of membrane-bound C3b and C3bi by viable human neutrophils (PMN). (1983) (16)
Inherited deficiencies of complement and complement-related proteins. (1986) (16)
Abdominal pain in hereditary angioedema: the role of acid hypersecretion. (1989) (14)
CD21 deficiency, complement, and the development of common variable immunodeficiency. (2012) (14)
Observations on the mechanism of immune hemolysis: importance of immunoglobulin class and source of complement on the extent of damage. (1970) (14)
Complement receptor expression by neoplastic and normal human cells. (1983) (14)
Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen. (1989) (14)
Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema (2010) (14)
Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. (2017) (14)
Role of complement in the pathophysiology of hematologic diseases. (1977) (13)
Complement Deficiencies of Laboratory Animals (1981) (13)
Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. (1983) (13)
The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levels. (1976) (13)
Complement: a brief review. (1989) (13)
Subcutaneous infusion of human C1 inhibitor in swine. (2010) (13)
Detection of complement in relation to disease. (1992) (12)
High dose intravenous immunoglobulin does not affect complement-bacteria interactions. (1998) (12)
A Receptor for Activated C3 in the Normal and Abnormal Human Renal Glomerular Capillary Wall (1976) (12)
Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes. (1987) (12)
Cold agglutinins and cold-agglutinin disease. (1977) (12)
A simplified method for purification of human C5a from citrated plasma. (1986) (12)
Animal models for complement deficiencies (1995) (11)
Complement factor 1 inhibitor improves cardiopulmonary function in neonatal cardiopulmonary bypass. (2007) (11)
Metabolic behavior of C3 in normal, C4-deficient (C4D) and cortisone-treated guinea pigs. (1974) (11)
The use of conglutinin in a quantitative assay for the presence of cell-bound C3bi and evidence that a single molecule of C3bi is capable of binding conglutinin. (1982) (11)
Update on preventive therapy (prophylaxis) for hereditary angioedema. (2013) (11)
Reticuloendothelial clearance of radiolabelled pneumococci in experimental bacteremia: correlation of changes in clearance rates, sequestration patterns, and opsonization requirements at different phases of the bacterial growth cycle. (1981) (11)
Studies on behavior. V. Actions of l-epinephrine and related compounds. (1959) (11)
Deficiencies of the Complement System (2014) (11)
Studies of antibody and complement function in host defense against bacterial infection. (1987) (10)
Urine-histamine levels in patients with hereditary angioedema (HAE). (1988) (9)
Anticomplement receptor activity in the serum of patients with primary biliary cirrhosis. (1986) (9)
Patients with bone marrow failure demonstrate decreased cutaneous reactivity to human C5a. (1987) (9)
An Overview of Novel Therapies for Acute Hereditary Angioedema (2010) (9)
Activation of the C3b receptor: effect of diacylglycerols and calcium mobilization. (1985) (9)
Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor. (1987) (9)
Complement Activation Influences Staphylococcus aureus Adherence to Endothelial Cells (2003) (9)
High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. (1991) (9)
Complement and the control of HIV infection: an evolving story (2014) (9)
Linkage of C4 Deficiency to the Major Histocompatibility Locus in the Guinea Pig (1976) (8)
Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues. (1985) (8)
Increased expression of Fc gamma RI on isolated PMN from individuals of African descent. (1993) (8)
Deficiency in C3b receptors on neutrophils of patients with chronic granulomatous disease and hyperimmunoglobulin-E recurrent infection (Job's) syndrome (1984) (8)
Immune complexes and the treatment of biliary cirrhosis. (1979) (8)
Increased expression of FcγRI on isolated PMN from individuals of African descent (1993) (8)
Site of deposition of C3 in Arthus reactions of C4 deficient guinea pigs. (1973) (8)
Hereditary angioedema: short-term prophylaxis for surgery. (2012) (8)
Genius at work: Osler's 1888 article on hereditary angioedema. (2010) (8)
C1 esterase inhibitor: clinical clues to the pathophysiology of angioedema. (1986) (8)
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. (2020) (8)
Studies of Human C 5 a as a Mediator of Inflammation in Normal Human Skin (8)
Immune Complexes: Normal Physiology and Role in Disease (2009) (7)
Studies of complement-mediated membrane damage: the influence of erythrocyte storage on susceptibility to cytolysis. (1973) (7)
Some Sources of Error in the Akerfeldt Test for Serum Oxidative Activity.∗ (1958) (7)
Immune Adherence by the Alternate Complement Pathway (1972) (7)
Immunostimulation of tumor cell growth: role of complement (1974) (7)
Hereditary C6 deficiency in man. (1973) (7)
Skin graft rejection and the arthus reaction in mice deficient in the third component (c'3) of complement. Abstr. (1965) (7)
Mechanisms by which HIV envelope minimizes immunogenicity (2011) (7)
Failure of cytotoxic agents to inhibit the clearance of sensitized erythrocytes. (1974) (7)
Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands. (2019) (6)
Complement Fixation by a Single Molecule of γG Hemolysin (1970) (6)
Spontaneous re-aggregation of IgM subunits and restoration of antibody activity after reduction and alkylation of rabbit anti-Forssman antibody. (1969) (6)
Studies of phagocytosis in chronic granulomatous disease (1987) (6)
A sensitive specific hemolytic assay for proenzyme C1. (1987) (6)
Hereditary angio-oedema (1993) (6)
CR1-receptor recycling in phorbol ester-activated polymorphonuclear leucocytes. (1988) (6)
Complement inclinical medicine (1975) (6)
The oxidative activity of blood serum in schizophrenic and manic-depressive psychoses. (1958) (6)
Distribution of complement receptors on human normal and malignant mononuclear cells. (1980) (6)
Homozygous C1 inhibitor deficiency: The conclusion of a long search. (2006) (6)
Linkage of the gene controlling the synthesis of the fourth component of complement to the major histocompatibility complex of the guinea pig (1976) (6)
Evidence that rabbit gamma G haemolysin in capable of utilizing guinea-pig complement more efficiently than rabbit gamma M haemolysin. (1970) (6)
Mechanism of bacterial resistance to serum killing (1982) (6)
Urticaria (Hives) and Angioedema (2011) (5)
New developments in immunopathology with special reference to complement and immune complexes. (1985) (5)
C1 inhibitor therapy and hereditary angioedema. (2010) (5)
Protease inhibitors of human plasma. C1-inhibitor (C1-INH). (1985) (5)
Immune Complexes and Allergic Disease (2009) (5)
Decline in rates of clearance of IgG-sensitized erythrocytes with increasing age. (1988) (5)
Terminal complement components play a role in the expression of C5a. (1987) (4)
Evasion of host defenses: group report. (1980) (4)
Fc-receptor dysfunction in lupus. (1979) (4)
Reduced concentrations of the first component of complement in hypotammaglobulinemia: correction of infusion of gamma-globulin. (1978) (4)
Binding of IgG-sensitized erythrocytes by mitral and aortic cardiac valves: a possible clue to the pathogenesis of immune valvular heart disease. (1981) (4)
Heparan Sulfate in Human Bruch’s Membrane/Choroid Tissue Increases the Rate of Proteolytic Cleavage of C3b by factors H and I (2009) (4)
The role of complement in the in vivo destruction of erythrocytes. (1980) (4)
Molecular Mechanisms in the Antibacterial Action of Complement (1986) (4)
Hereditary angioedema: implications of treating a rare disease. (2012) (4)
Studies of Immunologic Function in C4 Deficient Guinea Pigs (1971) (4)
Investigation of the Interactions Between Complement Factor H, C3b, and Amyloid β (2008) (4)
Complement and Hemolytic Antibody: Changes in Their Activity Induced by Mercaptoethanol (1965) (4)
Isolation and characterization of a novel plasma protein which binds to activated C4 of the classical complement pathway. (1989) (3)
Inherited deficiency of C8 in a patient with recurrent meningococcal infections: Further evidence for a dysfunctional C8 molecule and nonlinkage to the HLA system (2004) (3)
Danazol in the Treatment of Hereditary Angioedema (1980) (3)
A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition. (1987) (3)
C3b Inactivator: The Effect on Cell Bound C3b and a Simplified Functional Assay (1978) (3)
Renal Failure in Paroxysmal Hemoglobinuria (1974) (2)
Immune Complexes and Complement: Their Role in Host Defense and in Disease (2009) (2)
The C1 esterase inhibitor and hereditary angioedema (1982) (2)
Salmonella and Complement: The Critical Influence of O-Polysaccharide within LPS (1988) (2)
The Role of Complement in Host Defense Against Bacteremia (1978) (2)
Production and characterization of the monoclonal antibody against SGP120, a novel serum protein. (1996) (2)
The nature of allergy. (1968) (2)
Complement and arthritis: another step in understanding (2008) (2)
The relationship of complement to allergic disease. (1969) (2)
Haemophilus influenzae type b meningitis in a fully immunized 2-year-old. (2002) (2)
38 – Immune Complex–Mediated Diseases (2014) (2)
Complement deficiencies. (2000) (1)
Human serum sickness. (1984) (1)
The "neurotic" edema: the parent disease and its offspring. (2002) (1)
Electrophoretic differentiation of acquired angioedema from hereditary angioedema. (1987) (1)
Erratum to: Mechanisms by which HIV envelope minimizes immunogenicity (2011) (1)
Complement receptors and histamine degradation. (1980) (1)
Mechanism of antibody dependent serum killing of escherichia coli o 111b 4 (1982) (1)
Unraveling the Complement System and its Mechanism of Action (2014) (1)
Molecular Mimicry in the Pathogenicity of Microorganisms (1993) (1)
Evasion Strategies of Microorganisms (1989) (1)
Evidence for a New Cytotoxic Mechanism: The C1 Bypass Activator Pathway (1973) (1)
Purification and Metabolism of C1 Inhibitor and its Phenotypic Variants (1978) (1)
Diagnosis and Treatment of an American Cohort of Patients with Hereditary Angioedema (HAE) Type III (2011) (1)
103 – Complement in Control of Infectious Agents (2018) (1)
Studies on the mechanism of Staphylococcus resistance to complement-mediated killing—Terminal complement components C7, C8 and C9 are deposited and released from Reynolds without causing bacterial death (2007) (1)
THE COMPLEMENT SYSTEM IN CLINICAL DIAGNOSIS (1979) (1)
Biological Interactions of Complement with Endotoxin: Studies in C4-Deficient Guinea Pigs (1973) (1)
Studies of the biologic effects of selective C4 deficiency. (1975) (1)
Hereditary angioedema: The rewards of studying a rare disease (2004) (1)
Antibody Responses to a T Cell Dependent Antigen in C4 Deficiency (1978) (1)
Antibody dependent lymphoid cell mediated cytotoxicity. Abstr. (1972) (1)
Letter: Renal failure in paroxysmal hemoglobinuria. (1974) (1)
Monocyte fc receptors for immuno globulin g studied with monomeric iodine 125 labeled immuno globulin g 1 normal fcr expression in hla b 8 drw 3 individuals (1982) (0)
The reticuloendothelial system and autoimmune disease in man. (1985) (0)
Modulation of complement-mediated tissue injury by IVIG (1997) (0)
The Effects of Heparin and Heparan Sulfate on the Complement Regulatory Activity of Factor H (2006) (0)
Supplementary Material for: Novel Adenovirus Vectors ‘Capsid-Displaying’ a Human Complement Inhibitor (2017) (0)
IgG Fc Receptor Activity in vivo is Under Complement Control (2012) (0)
Binding of immunoglobulin- and complement-coated erythrocytes to human neutrophil subpopulations (1981) (0)
Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8. (2005) (0)
Functional Analysis of the Y402H Variant of Complement Factor H: Implications for Risk of Age–Related Macular Degeneration. (2006) (0)
Introduction: New Perspectives in Hereditary Angioedema (HAE): Molecular Mechanisms & Therapeutic Choices: A CME Symposium Presented at the 2009 World Allergy Congress, Buenos Aires, Argentina, December 9, 2009 (2010) (0)
Mechanism of the Damage‐Producing Steps of Immune Haemolysis (2008) (0)
Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9. (2004) (0)
vivo clearance High-dose intravenous immunoglobulin modifies complement-mediated in (2011) (0)
Evasion mechanisms of bacteria. (2006) (0)
Anti-complement receptors in PBC in the clearance of complement coated cells in primary biliary cirrhosis (2006) (0)
2,3,7,8-tetrachlorodibenzo-p-dioxin and natural immunity: lack of an effect on the complement system in a guinea pig model. (2001) (0)
Forssman shock in C2-deficient (C2D) guinea pigs: Role of a C2-bypass pathway (1998) (0)
Mechanism of Complement Activation By PF4/ Heparin Complexes (2016) (0)
104 Cutaneous manifestations of human serum sickness (1985) (0)
SUPPLEMENT Recombinant and Plasma-Purified Human C 1 Inhibitor for the Treatment of Hereditary Angioedema (2015) (0)
Book ReviewAn Introduction to the Neurosciences. (1972) (0)
Book ReviewClinical Immunology Update: Reviews for physicians (1980) (0)
Editorial Complement and arthritis: another step in understanding (2008) (0)
1012. Ad Interactions with the Complement Systems of Humans and Mice (2004) (0)
Control of Complement-Mediated Tissue Damage by γ-Globulin: Application in Xenotransplantation (1997) (0)
Development of humanized complement factor H transgenic mice to interrogate the effect of age-related macular degeneration risk associated variants in vivo (2012) (0)
The Function of the Reticuloendothelial System in Autoimmune Disease (1983) (0)
Recycling of CR1 by phorbol ester-activated polymorphonuclear leukocytes (PMN) (1986) (0)
Guinea Pig Model Functionally Active C 2-Bypass Pathway in a Damage in the Absence of C 2 : Evidence of a IgG and Complement-Mediated Tissue (1999) (0)
Studies of the interaction of antibody and complement with encapsulated bacteria. (1986) (0)
An IGG FC fragment peptide blocks interaction of IGG with C1Q (2000) (0)
Concentration and Composition Changes in Heparan Sulfate Increase Complement Activation Through Modulation of C3bBb Convertase Formation and This Effect is Modified by Factor H (2011) (0)
93 A novel approach for the purification of Cl-inhibitor from human plasma (1983) (0)
Structure of MntC from cyanobacteria (2005) (0)
The role of C1 in the regulation of immune complex binding to FcγRIIA (2007) (0)
Detection of DAF-RBC in PNH Blood (2003) (0)
Transient deficiency of complement factor D function in infancy (2005) (0)
I I . RELATIVE RATES OF APPEARANCE OF LYMPHOCYTES BEARING SURFACE IMMUNOGLOBULIN AND COMPLEMENT RECEPTORS BY MICHAEL C. GELFAND,* (2003) (0)
Efficacy and Safety of a C1 Esterase Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary Angioedema: Findings from a Large International Registry (2015) (0)
Complement fixation by a single molecule of gamma G hemolysin. (1970) (0)
F.105. C1q and the Classical But Not Alternative Complement Pathways Control the Binding of Immune Complexes (IC) to IgG Fc Receptors (FcγR) (2006) (0)
I N Vitro Studies of C O M P L E M E N T Function I N Sera of C 4 -d E F I C I E N T Guinea Pigs (0)
Monocyte fc receptors for immuno globulin g are increased in auto immune hemolytic anemia (1982) (0)
Manipulation of the Humoral Immune System and the Host Immune Response to Infection (2001) (0)
Studies of reticuloendothelial system function in immune complex disease. (1979) (0)
407. Complement Blockade Prevents Several Innate Toxicities Rapidly Induced after Intravenous Adenovirus (Ad) Vector Administration (2005) (0)
Structure determination of proteins involved in the stability of phycobilisomes during environmental stress (2005) (0)
Immune Complex-Mediated Damage Is Under Complement Pathway Control (2013) (0)
Role of complement in cold agglutinin disease (1975) (0)
Age-Related Macular Degeneration Alternative Pathway: Implications for Membrane, Inhibits the Complement Heparan Sulfate, Including That in Bruch's (2010) (0)
A receptor for activated C3 in the human renal glomerular capillary wall. (1975) (0)
O N T O G E N Y OF B L Y M P H O C Y T E S I I . RELATIVE RATES OF APPEARANCE OF LYMPHOCYTES BEARING SURFACE IMMUNOGLOBULIN AND COMPLEMENT RECEPTORS (1974) (0)
Serum Chemotactic Factors in an Animal Model of a Complement Deficiency State (1973) (0)
INTERACTION OF HELICOBACTER PYLORI (HP) WITH HUMAN COMPLEMENT: 95 (1997) (0)
Iconographies supplémentaires de l'article : CD21 deficiency, complement, and the development of common variable immunodeficiency (2012) (0)
Answers for march CME article (1992) (0)
Evidence that the nurse shark C4 inhibitor is a C1S like molecule (1998) (0)
Management of Hereditary Angioedema in Childhood: A Review (2014) (0)
Effect Of Excess Complement Inhibition On AMD-like Pathology Using The APOE4/sCrry Transgenic Murine Model: Does Gain-of-function Worsen Retinal Disease? (2011) (0)
HEREDITARY ANGIOEDEMA: IDENTIFYING THE CAUSE AND CURE (2013) (0)
Contributors (2012) (0)
An Apple a Day Could Keep the Hepatic Abscess Away: A Rare Etiology for a Rare Finding in an Immunocompetent Patient: 831 (2010) (0)
Modulation of the alternative complement pathway by C1 inhibitor (C1 INH) (2000) (0)
TABLE I Comparison of Survival in Normal and Splenectomized Guinea Pigs (0)
The Influence of Heparin, Heparan Sulfate, and C-reactive Protein on the Cofactor Activity of Complement Factor H (402HH and 402YY) (2007) (0)
MECHANISM OF SERUM RESISTANCE IN BACTERIA Serum (2003) (0)
Contributors (2018) (0)
Clinical and laboratorv studies Cutaneous manifestations of serum sickness patients receiving antithymocyte globulin (1985) (0)
Affect Complement-Bacteria Interactions High Dose Intravenous Immunoglobulin Does Not (1998) (0)
Enhancing academic allergy/immunology faculty and training programs☆ (1991) (0)
Erratum: 'Abdominal pain in hereditary angioedema: The role of hypersecretion' (Am. J. Gastroenterol. 84: 873-877, 1989) (1990) (0)
Biological effects of anti-pneumococcal (Pn) antibody and complement in Pn bacteremia (1982) (0)
Demonstration of Defective C 3-Receptor-mediated Clearance by the Reticuloendothelial System in Patients with Acquired Immunodeficiency Syndrome (2013) (0)
105 – Infectious Complications of Complement Deficiencies (2012) (0)
Comparison of binding of factors B and H to C3b on Salmonellae differing in their O-antigen polysaccharide (O-PS) structure (1986) (0)
The classical and alternative complement pathways play different roles in the immune response (2010) (0)
Hereditary angioedema (2005) (0)
Influences Efficiency of Phagocytosis Membrane Complement Receptors To Interact with Staphylococcus aureus Availability of Complement Bound to (2003) (0)
Multimeric complement component C 9 is necessary for killing of Escherichia coli J 5 by terminal attack complex C 5 b9 [ poly ( C 9 ) / complement-mediated bacterial killing ] (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael M. Frank?

Michael M. Frank is affiliated with the following schools:

Michael M. Frank's Academic­Influence.com Rankings

Why Is Michael M. Frank Influential?

Michael M. Frank's Published Works

Published Works

What Schools Are Affiliated With Michael M. Frank?

Michael M. Frank's AcademicInfluence.com Rankings